N/A N=100 Amsterdam Stool Scale: Usefulness in Clinical Setting
Stool Assessment
Primary: Interrater Variability (IV) — 0.79; 0.87; 0.81; 0.44 kappa value
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=96 Study of Stool Patterns to Collect a Panel of Stool Images for the Development of a Software
Healthy
Primary: Total Number of Stool Images Collected — 2731 images
N/A N=50 Stool Sampling in the Acute Isolated Patient , Efficient Acquiring With a Novel Device
Feasibility Study
Primary: Number of Participants With Stool Sample Acquired — 46 Participants
N/A N=121 The Nordic Consensus Study
Stoma Site Leakage · Quality of Life · Nurse's Role
Primary: Evaluate Body Assessment Tool Based on the Nurse Evaluation Form — 4.6; 5.1; 4.7 score on a scale
N/A N=28 A Clinical Investigation Examining the Performance and Handling of New 2-piece Ostomy Products in 28 People With an Ileostomy.
Ileostomy - Stoma
Primary: Degree of Leakage — 6.4; 3.4; 7.0; 7.0 units on a scale
N/A N=99,314 Screening for Stomach Diseases and Colorectal Neoplasms With the Fecal Testing
Colorectal Cancer · Stomach Disease
Primary: Incidence of Stomach Cancer — 49; 59 Participants
N/A N=22 Investigation of the Performance and Safety of New 1-piece Open Ostomy Appliances Compared to Standard Care
Ileostomy - Stoma
Primary: Degree of Leakage — 4; 4.6; 2.6 units on a scale
Phase 4 N=23 Changes in Bile Acid Homeostasis and Stool Habits After Cholecystectomy
Bile Acid Malabsorption · Cholelithiasis
Primary: Change in Stimulated Fibroblast Growth Factor 19 (FGF19) From Baseline Before Versus Post Cholecystectomy — 81; 186 pg per mL — p=0.03
N/A N=22 An Exploratory Study Investigating Human Skin Reaction to Output
Ileostomy
Primary: Trans Epidermal Water Loss After Test of Patches. — 45.8; 22.9; 36.8; 19.6 g/m^2/h
Phase 4 N=13 Ability of Mayo Clinic High-performance Liquid Chromatography (HPLC) Method to Measure Fecal Bile Acids
Diarrhea Predominant Irritable Bowel Syndrome
Primary: Change in Total 48 Hour Fecal Bile Acids (BA) From Baseline in Response to Treatment With Colesevelam — 1662; 3496 uM — p=0.012
N/A N=264 Colorectal Cancer Screening Assessment Study
Colorectal Cancer
Primary: Use of FOBT ColoCARE Home Kit — 14; 2; 14; 0 participants
N/A N=200 Fecal Incontinence Treatment (FIT) Study
Fecal Incontinence · Bowel Incontinence
Primary: Treatment Response Defined as a 75% or Greater Change in Number of Average Weekly FI Episodes at Month 3 Follow-Up Compared to Baseline — 29; 28 Participants
N/A N=12 Proof of Concept: "Bottom's Up" Seat to Treat Constipation
Constipation Aggravated · Pelvic Floor; Incompetency
Primary: Adverse Events — 0 Participants
Phase 2 N=11 Fat Malabsorption in Chronic Pancreatitis
Chronic Pancreatitis
Primary: Malabsorption Blood Test: Difference in Mean HA AUC Between Groups: Subjects With CP Compared to Healthy Subjects — 8.3; 17.7 mg*h/dL — p=<0.001
Phase 3 N=300 Controlling Anal Incontinence by Performing Anal Exercises With Biofeedback or Loperamide (CAPABLe)
Fecal Incontinence
Primary: Change From Baseline St. Mark's (Vaizey) Score — -5.5; -4.4; -4.5; -3.4 units on a scale — p=0.092
N/A N=101 An Observational Study of Fecal Calprotectin as Clinical Tool in Monitoring Moderate-to-severe Crohn's Disease on Adalimumab Induction Therapy: a KoRean Experience (FAIR)
Crohn's Disease
Primary: Percentage of Participants With Fecal Calprotectin Less Than 150 Microgram/Gram — 16.30; 13.25 Percentage of participants
N/A N=23 Assessment of New Enhanced Ostomy Device in Real-life Settings in Subjects Having a Stoma
Ileostomy - Stoma · Colostomy Stoma
Primary: Trans Epidermal Water Loss — 39.0; 35.9 g/m^2/h
Phase 2 N=10 Fecal Microbiota Transplantation for the Treatment of Primary Sclerosing Cholangitis.
Sclerosing Cholangitis
Primary: Adverse Event Frequency — 8 Participants
N/A N=50 Utility of an Animated Bowel Biofeedback Training Routine to Improve Bowel Function in Individuals With SCI
Spinal Cord Injury · Constipation · Fecal Incontinence
Primary: Baseline Motility (Anorectal Sensation and Strength) Characteristics — 105; 34.4; 30; 77.9 mmHg
N/A N=20 The Use of an "Anal-Tape" in Patients With Fecal Incontinence
Fecal Incontinence
Primary: Any Improvment in the Fecal Incontince Quality of Life Scale (FIQoLs) — 2.8; 3.3; 1.9; 2.5 score on a scale
N/A N=404 Interventions to Improve Colorectal Cancer Screening
Colorectal Neoplasms
Primary: Colorectal Cancer Screening — 127; 112 participants — p=0.01
N/A N=983 An Evaluation of a Multi-target Stool DNA (Mt-sDNA) Test, Cologuard, for CRC Screening in Individuals Aged 45-49 and at Average Risk for Development of Colorectal Cancer: Act Now
Colorectal Cancer
Primary: Specificity of the Multi-target Stool DNA Test in Average Risk Population, Ages 45-49 — 95.3 percentage of participants
N/A N=180 Efficacy and Acceptability of Low-Residue Diet Package (Enimaclin®) as Diet Control Before Colonoscopy
Dietary Modification
Primary: Overall Cleansing Level at Colonoscopy by Ottawa Bowel Preparation Scale — 2.58; 3.22; 2.97 units on a scale — p=0.435
N/A N=31 Correlation of Anal Acoustic Reflectometry Parameters With Degree of Rectal Intussusception and Prolapse
Pelvic Floor Disorders
Primary: Opening Pressure — 56.35; 39.01; 23.42 cmH20
N/A N=79 Comparative Study Between Two Fecal Management Systems
Anal Erosion
Primary: Number of Patients With Anal Erosion Within 14 Days After Insertion of FMS — 5; 5 Participants
Phase 2 N=114 Colon Staining Efficacy of Single Oral Doses of Methylene Blue MMX
Colon Staining in Preparation for Colonoscopy
Primary: Evaluation of Mucosal Staining Efficacy — 6.8; 2.3; 8.1; 7.0 scores on a scale
N/A N=72 Bowel Function After Minimally Invasive Urogynecologic Surgery
Functional Disorder of Intestine
Primary: Time to First Post-op Bowel Movement — 64; 77 hours
N/A N=52 Stapled TransAnal Rectal Resection (STARR) With Contour® TranstarTM
Obstructed Defecation Syndrome · Rectocele · Intussusception
Primary: Quality of Life — 3.2; 3.7; 2.8; 3.3 units on a scale — p=0.1340
N/A N=600 Clinical Staging Tools for the Impacts of Obesity on Individuals
Morbid Obesity
Primary: Changes in Obesity Scores After Weight Loss Treatment — 600 Participants
Phase 4 N=75 Study of Stapled Transanal Rectal Resection (STARR) Surgery in Refractory Constipation Associated With Obstructive Defecation Syndrome (ODS)
Obstructive Defecation Syndrome · Chronic Constipation · Rectocele
Primary: Percentage of Change (Reduction) in Total ODS Symptom Composite Score From Baseline to One Year Post Procedure — 60.8 percentage of change